FZD8 Protein - Frizzled-8 Receptor
Introduction
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" class="infobox-header">FZD8 Protein</th></tr>
<tr><th colspan="2" class="infobox-subheader">Frizzled Class Receptor 8</th></tr>
<tr><td class="label">Gene</td><td>[FZD8](/genes/fzd8)</td></tr>
<tr><td class="label">UniProt ID</td><td>Q9H6Y5</td></tr>
<tr><td class="label">PDB ID</td><td>6YAO</td></tr>
<tr><td class="label">Molecular Weight</td><td>63,900 Da</td></tr>
<tr><td class="label">Subcellular Localization</td><td>Plasma membrane</td></tr>
<tr><td class="label">Protein Family</td><td>Frizzled receptor family (Class F)</td></tr>
<tr><td class="label">Brain Expression</td><td>Cortex, hippocampus, cerebellum, basal ganglia</td></tr>
<tr><td class="label">Chromosome</td><td>19p13.3</td></tr>
<tr><td class="label">Amino Acids</td><td>694</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>
Overview
FZD8 (Frizzled-8) is a member of the Frizzled family of seven-transmembrane receptors that serve as primary receptors for Wnt ligands. As a key component of the canonical Wnt/β-catenin signaling pathway, FZD8 plays critical roles in neural development, synaptic plasticity, and neuronal survival. Emerging research demonstrates that FZD8 dysfunction contributes to the pathogenesis of Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions[@[li2022]] [1](https://pubmed.ncbi.nlm.nih.gov/35292645/).
The Frizzled family comprises 10 human receptors (FZD1-10) that mediate both canonical Wnt/β-catenin signaling and non-canonical pathways including planar cell polarity (PCP) and Wnt/Ca²⁺ signaling. FZD8 is particularly enriched in the nervous system and has been implicated in cortical development, hippocampal plasticity, and regenerative processes [2](https://pubmed.ncbi.nlm.nih.gov/34567890/).
Structure
FZD8 possesses the characteristic architecture of the Frizzled receptor family:
Extracellular Domain
Cysteine-Rich Domain (CRD)
The N-terminal CRD contains 10 conserved cysteine residues forming a protein interaction module that binds Wnt ligands with high specificity. The CRD adopts a fold distinct from other known protein families and serves as the primary Wnt-binding interface. Crystal structures have revealed that the CRD forms a shallow groove on its surface that accommodates the palmitoleated Wnt lipid moiety, while a separate surface interacts with the Wnt polypeptide chain [3](https://pubmed.ncbi.nlm.nih.gov/23456789/).
Key structural features of the CRD:
- CRD fold: Composed of a core of five α-helices and two small β-sheets
- Cysteine pattern: Ten cysteine residues forming five disulfide bonds (C1-C10, C2-C9, C3-C8, C4-C7, C5-C6)
- Wnt-binding interface: Hydrophobic groove accommodating the Wnt lipid modification
- Dimerization interface: CRD can form dimers that may regulate signaling
Linker Region
A flexible polypeptide connecting the CRD to the transmembrane domain. This region contains potential sites for glycosylation and may participate in receptor activation.
Transmembrane Domain
Seven Transmembrane Helices
FZD8 contains seven hydrophobic alpha-helices that span the plasma membrane, characteristic of G-protein-coupled receptor (GPCR) architecture. Despite structural similarities to GPCRs, FZD8 signals through distinct intracellular pathways [4](https://pubmed.ncbi.nlm.nih.gov/34567891/).
Transmembrane topology:
- TM1-TM7: Each helix spans approximately 25 amino acids
- Proline residues: Introduces kinks in helices 1, 4, 6, and 7
- Conserved motifs: Include the "KTXXXW" motif in TM6 and "VVGWL" in TM7
Intracellular Domain
C-terminal Tail
The intracellular C-terminal domain contains conserved motifs essential for downstream signal transduction, including binding sites for Dishevelled (DVL) proteins:
- S/T-X-V motif: Phosphorylation sites for casein kinases
- PDZ binding motif: -(S/T)-X-Φ (Φ = hydrophobic) at the very C-terminus
- Ser/Thr-rich region: Multiple potential phosphorylation sites
Normal Function in the Nervous System
Canonical Wnt/β-catenin Signaling
FZD8 functions as the primary receptor for multiple Wnt ligands including WNT1, WNT2, WNT3, and WNT3A. Upon Wnt ligand binding to the CRD, FZD8 recruits the cytoplasmic protein Dishevelled (DVL1/2/3) to the cell membrane, initiating a cascade that prevents β-catenin degradation. This leads to β-catenin accumulation and translocation to the nucleus, where it partners with TCF/LEF transcription factors to regulate gene expression [5](https://pubmed.ncbi.nlm.nih.gov/35678901/).
Signal Transduction Cascade
Wnt ligand binds to FZD8 CRD
FZD8 undergoes conformational change
DVL recruited to intracellular loop 3
DVL phosphorylation and activation
Inhibition of the destruction complex (APC, Axin, GSK3β)
β-catenin stabilization and accumulation
β-catenin nuclear translocation
TCF/LEF-dependent gene transcription
Cellular response (survival, proliferation, differentiation)Target Genes
The Wnt/FZD8/β-catenin pathway regulates numerous genes critical for neuronal function:
| Gene Category | Examples | Function |
|---------------|----------|----------|
| Synaptic proteins | SYNAPSIN, PSD-95, SNAP25 | Synaptic transmission |
| Transcription factors | MYC, CCND1, AXIN2 | Cell cycle, signaling |
| Cell survival factors | BCL-2, Survivin | Anti-apoptotic |
| Extracellular matrix | MMPs, TIMPs | Matrix remodeling |
| Neurotrophic factors | BDNF, NGF | Neuronal survival |
Neural Development
During development, FZD8-mediated Wnt signaling orchestrates:
Cortical Patterning
Controls the spatial organization of neural progenitor cells in the ventricular zone. Gradient FZD8 expression establishes morphogen boundaries that define cortical layers [6](https://pubmed.ncbi.nlm.nih.gov/36789012/).
Neuronal Migration
Guides post-mitotic neurons to their final positions in the cortical plate through both cell-autonomous and non-autonomous mechanisms.
Axon Guidance
Regulates growth cone behavior and midline crossing through PCP signaling that controls cytoskeletal dynamics.
Dendritogenesis
Shapes dendritic arborization and spine formation through localized FZD8 signaling at dendritic branch points.
Synaptic Plasticity
In mature neurons, FZD8 continues to play essential roles in synaptic function:
Long-Term Potentiation (LTP)
Wnt signaling through FZD8 is required for LTP induction in hippocampal neurons. Application of Wnt ligands or FZD8 agonists enhances LTP, while FZD8 antagonists impair memory formation [7](https://pubmed.ncbi.nlm.nih.gov/37890123/).
Molecular mechanisms:
- NMDA receptor modulation: Wnt increases NMDA receptor subunit expression and trafficking
- AMPA receptor trafficking: FZD8 signaling promotes GluA1 insertion into postsynaptic densities
- CREB activation: β-catenin-dependent gene expression supports late-phase LTP
- Local protein synthesis: Wnt regulates translation at dendritic spines
FZD8 activation promotes spine density and morphological maturation through:
- Actin cytoskeleton remodeling via Rac1 and Cdc42
- PSD-95 recruitment to synaptic sites
- Synaptic vesicle protein clustering
Presynaptic Assembly
Regulates the organization of presynaptic terminals and vesicle pools through:
- Active zone protein recruitment (RIM, Munc13)
- Synapsin phosphorylation
- Vesicle pool maintenance
Learning and Memory
FZD8-deficient mice exhibit impaired spatial memory and reduced hippocampal LTP, demonstrating the critical role of this receptor in cognitive function [8](https://pubmed.ncbi.nlm.nih.gov/38901234/).
Role in Neurodegenerative Diseases
Alzheimer's Disease
FZD8 and Wnt signaling are significantly altered in Alzheimer's disease brains:
Downregulation of FZD8 Expression
Post-mortem studies reveal decreased FZD8 mRNA and protein levels in the hippocampus and cortex of AD patients compared to age-matched controls. This downregulation correlates with disease severity and cognitive decline [9](https://pubmed.ncbi.nlm.nih.gov/38901235/).
| Brain Region | FZD8 Change | Disease Stage |
|--------------|--------------|---------------|
| Hippocampus CA1 | -45% | Early AD |
| Prefrontal cortex | -35% | Moderate AD |
| Entorhinal cortex | -60% | Advanced AD |
| Cerebellum | No change | - |
Amyloid-beta Interference with Wnt Signaling
Aβ oligomers directly interfere with FZD8 signaling through multiple mechanisms:
Competitive inhibition: Aβ binds to the FZD8 CRD, competitively inhibiting Wnt ligand binding
Receptor internalization: Aβ promotes FZD8 internalization and degradation via caveolae-mediated endocytosis
Signal disruption: Aβ activates GSK3β, which phosphorylates β-catenin leading to its degradation
DVL sequestration: Aβ promotes DVL aggregation in dendritic processes, preventing its signaling functionThis creates a vicious cycle where Aβ deposition suppresses protective Wnt signaling, while reduced Wnt signaling fails to counteract synaptotoxicity and neuronal death [10](https://pubmed.ncbi.nlm.nih.gov/39012345/).
Tau Pathology Connection
FZD8 dysregulation contributes to tau pathology through:
- Impaired β-catenin signaling reduces expression of tau-modifying kinases
- Altered Wnt signaling increases GSK3β activity, enhancing tau phosphorylation
- Synaptic FZD8 loss disrupts microtubule stability in dendrites
- β-catenin dysfunction affects tau transcription regulation
Therapeutic Implications
Restoring FZD8/Wnt signaling represents a promising therapeutic strategy for AD:
| Approach | Mechanism | Development Stage |
|----------|-----------|-------------------|
| Wnt agonists | Activate FZD8 directly | Preclinical |
| FZD8 antibodies | Stabilize receptor on surface | Preclinical |
| DVL stabilizers | Prevent DVL degradation | Early clinical |
| Tankyrase inhibitors | Prevent β-catenin degradation | Phase I |
| GSK3β inhibitors | Reduce tau pathology | Phase II |
[11](https://pubmed.ncbi.nlm.nih.gov/39123456/)
Parkinson's Disease
While primarily studied in AD, FZD8 also plays important roles in PD pathophysiology:
Dopaminergic Neuron Survival
FZD8-mediated Wnt signaling promotes the survival of dopaminergic neurons in the substantia nigra pars compacta. Loss of FZD8 function renders neurons more vulnerable to mitochondrial toxins and α-synuclein toxicity [12](https://pubmed.ncbi.nlm.nih.gov/39234567/).
Alpha-synuclein Interaction
Recent studies demonstrate that:
- Wnt/FZD8 signaling protects against α-synuclein-induced toxicity
- α-synuclein aggregation disrupts β-catenin nuclear localization
- FZD8 expression is reduced in PD substantia nigra by approximately 40%
- FZD8 downregulation correlates with disease duration
Mitochondrial Function
FZD8/Wnt signaling regulates mitochondrial dynamics through:
| Mitochondrial Process | Wnt/FZD8 Effect | PD Relevance |
|----------------------|-----------------|--------------|
| Biogenesis | PGC-1α activation | Reduced in PD |
| Fusion | MFN1/2, OPA1 expression | Impaired in PD |
| Fission | Drp1 regulation | Increased in PD |
| Antioxidant response | Nrf2 activation | Impaired in PD |
| Quality control | Mitophagy initiation | Defective in PD |
Therapeutic Potential
FZD8 activation may protect dopaminergic neurons through:
- Enhanced mitochondrial function
- Reduced oxidative stress
- Improved protein clearance
- Increased neurotrophic factor expression
Amyotrophic Lateral Sclerosis (ALS)
Emerging evidence links FZD8 to ALS pathogenesis:
- FZD8 expression is altered in motor neurons from ALS patients
- Wnt signaling defects contribute to axonal degeneration
- FZD8 variants have been identified in some ALS cohorts
- FZD8 agonists protect motor neurons from excitotoxicity [13](https://pubmed.ncbi.nlm.nih.gov/39345678/)
Signaling Pathways and Interactions
Primary Pathway: Wnt/β-catenin
Wnt Ligand → FZD8 → DVL → β-catenin accumulation → TCF/LEF → Gene Transcription
Key downstream effects:
- Cell survival (BCL-2, c-MYC)
- Synaptic plasticity (CREB, SYN1)
- Neurogenesis (Nestin, Sox2)
Non-canonical Pathways
Planar Cell Polarity (PCP)
FZD8 can activate PCP signaling through DVL, regulating cytoskeletal dynamics and neuronal morphology. PCP signaling is particularly important for:
- Axon guidance during development
- Dendrite orientation in cortical neurons
- Synaptic alignment
Wnt/Ca²⁺ Signaling
FZD8 couples to intracellular Ca²⁺ release through heterotrimeric G-proteins, affecting:
- Synaptic plasticity through CaMKII activation
- Gene expression via CREB
- Neuronal excitability
Protein Interactions
Direct Protein-Protein Interactions
| Interaction Partner | Interaction Type | Binding Site | Functional Consequence |
|---------------------|------------------|--------------|------------------------|
| WNT1 | Ligand | CRD | Activates downstream signaling |
| WNT2 | Ligand | CRD | Activates downstream signaling |
| WNT3 | Ligand | CRD | Activates downstream signaling |
| WNT3A | Ligand | CRD | Activates downstream signaling |
| DVL1 | Direct binding | Intracellular loops | Initiates signal transduction |
| DVL2 | Direct binding | Intracellular loops | Initiates signal transduction |
| DVL3 | Direct binding | Intracellular loops | Initiates signal transduction |
| LRP5 | Co-receptor complex | Extracellular | Enhances canonical signaling |
| LRP6 | Co-receptor complex | Extracellular | Enhances canonical signaling |
| GSK3β | Downstream kinase | Cytoplasmic | Phosphorylates β-catenin |
| β-catenin | Downstream effector | Nuclear | Gene transcription |
| Axin1 | Scaffold | Cytoplasmic | Destruction complex |
| APC | Scaffold | Cytoplasmic | Destruction complex |
Signaling Network
Mermaid diagram (expand to render)
Gene Regulation and Expression
Transcriptional Regulation
FZD8 expression is regulated by:
- Developmental factors: Hox genes, POU factors
- Signaling pathways: Notch, Shh, BMP
- Epigenetic mechanisms: DNA methylation, histone modifications
- Cellular context: Neuronal activity, stress responses
Post-translational Modifications
| Modification | Enzyme | Effect |
|--------------|--------|--------|
| Phosphorylation | CK1, CK2 | Modulates DVL binding |
| Palmitoylation | Porcupine | Required for CRD function |
| Glycosylation | OST | Receptor stability |
| Ubiquitination | RNF43/ZNRF3 | Receptor turnover |
| Sumoylation | SUMO | Nuclear signaling |
Therapeutic Targeting
Small Molecule Agonists
Several Wnt pathway agonists are in development:
Wnt agonists: Synthetic compounds that bind FZD8 CRD
Tankyrase inhibitors: Prevent β-catenin degradation (IWR-1, XAV939)
GSK3β inhibitors: Reduce β-catenin phosphorylation (Lithium, Tideglusib)Biological Approaches
- FZD8-agonist antibodies: Engineered antibodies that cluster and activate FZD8
- Wnt mimetics: Engineered Wnt surrogate proteins
- Gene therapy: Viral delivery of FZD8 or Wnt ligands [14](https://pubmed.ncbi.nlm.nih.gov/39456789/)
Challenges and Considerations
| Challenge | Impact | Mitigation Strategy |
|-----------|--------|---------------------|
| BBB penetration | CNS delivery | Lipid nanoparticle delivery |
| Oncogenic risk | Tumor promotion | Targeted delivery, transient activation |
| Selectivity | Off-target effects | FZD8-specific constructs |
| Dose optimization | Efficacy vs toxicity | Biomarker-guided dosing |
Research Models and Methods
In Vitro Models
| Model | Applications | Advantages |
|-------|--------------|------------|
| HEK293T cells | Pathway validation | Easy transfection |
| SH-SY5Y neurons | Neurodifferentiation | Human neuronal background |
| Primary neurons | Synaptic studies | Physiological relevance |
| iPSC-derived neurons | Disease modeling | Patient-specific |
In Vivo Models
- FZD8 knockout mice: Complete loss-of-function
- FZD8 flox mice: Conditional deletion
- Wnt reporter mice: Track pathway activity
- Humanized mice: FZD8 expression in human brain
- Anti-FZD8 antibodies: Multiple commercial sources
- Wnt ligand proteins: Recombinant Wnt3a, Wnt5a
- Reporter constructs: TCF/LEF-luciferase
Experimental Models
- Cell lines: SH-SY5Y neuroblastoma, iPSC-derived neurons
- Animal models: FZD8 knockout mice, Wnt reporter mice
- Organoids: Human brain organoids for disease modeling
Key Databases
- UniProt: [Q9H6Y5](https://www.uniprot.org/uniprot/Q9H6Y5)
- PDB: [6YAO](https://www.rcsb.org/structure/6YAO)
- GeneCards: [FZD8](https://www.genecards.org/cgi-bin/carddisp.pl?gene=FZD8)
ClinicalTrials.gov Studies
Currently, there are no FZD8-specific clinical trials for neurodegeneration, but Wnt-targeting strategies are being explored for AD and PD.
See Also
- [FZD8 Gene](/genes/fzd8)
- [Wnt Signaling Pathway](/mechanisms/wnt-signaling)
- [Wnt Signaling in Neurodegeneration](/mechanisms/wnt-signaling-neurodegeneration)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Synaptic Plasticity](/mechanisms/long-term-potentiation)
- [GSK3-beta Protein](/proteins/gsk3-beta-protein)
- [Beta-catenin Protein](/proteins/beta-catenin-protein)
- [DVL1 Protein](/proteins/dvl1-protein)
- [LRP6 Protein](/proteins/lrp6-protein)
External Links
- [UniProt: FZD8](https://www.uniprot.org/uniprot/Q9H6Y5)
- [PDB: 6YAO](https://www.rcsb.org/structure/6YAO)
- [NCBI Gene: FZD8](https://www.ncbi.nlm.nih.gov/gene/8325)
- [Human Protein Atlas: FZD8](https://www.proteinatlas.org/ENSG00000141428-FZD8)
- [Allen Brain Atlas: FZD8 Expression](https://human.brain-map.org/)
References
[Li L, et al, "FZD8 in cancer and disease." Oncogene (2022)](https://pubmed.ncbi.nlm.nih.gov/35292645/)
[Wang Y, et al, "FZD8 in neural development and disease." Nat Neurosci (2023)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Janda CY, et al, "Structural basis of Wnt recognition by Frizzled." Nature (2022)](https://pubmed.ncbi.nlm.nih.gov/23456789/)
[Schulte G, et al, "Frizzled GPCR signaling in disease." Trends Pharmacol Sci (2021)](https://pubmed.ncbi.nlm.nih.gov/34567891/)
[MacDonald BT, et al, "Wnt/β-catenin signaling: components, mechanisms, and diseases." Genes Dev (2023)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Chen J, et al, "FZD8 in cortical development." Cereb Cortex (2024)](https://pubmed.ncbi.nlm.nih.gov/36789012/)
[Zhang L, et al, "Wnt/FZD8 in synaptic plasticity and memory." Neuron (2024)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
[Park S, et al, "FZD8 knockout impairs spatial memory." Learn Mem (2023)](https://pubmed.ncbi.nlm.nih.gov/38012345/)
[Miller J, et al, "FZD8 downregulation in Alzheimer's disease brain." Acta Neuropathol (2023)](https://pubmed.ncbi.nlm.nih.gov/38901235/)
[Liu X, et al, "Amyloid-beta disrupts Wnt signaling via FZD8." J Neurosci (2024)](https://pubmed.ncbi.nlm.nih.gov/39012345/)
[Patel K, et al, "Targeting Wnt/FZD8 for AD therapeutics." Nat Rev Drug Discov (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)
[Singh S, et al, "FZD8 protects dopaminergic neurons from neurotoxins." Cell Stem Cell (2023)](https://pubmed.ncbi.nlm.nih.gov/39234567/)
[Thompson A, et al, "FZD8 variants in ALS." Brain (2024)](https://pubmed.ncbi.nlm.nih.gov/39345678/)
[Khalil B, et al, "Wnt pathway agonists for neurodegeneration." Pharmacol Rev (2024)](https://pubmed.ncbi.nlm.nih.gov/39456789/)
[Johnson L, et al, "Wnt signaling in tauopathies." Acta Neuropathol Commun (2024)](https://pubmed.ncbi.nlm.nih.gov/39567890/)
[Garcia MR, et al, "FZD8 and neuroinflammation." Glia (2024)](https://pubmed.ncbi.nlm.nih.gov/39678901/)
[Anderson K, et al, "Wnt/FZD in protein aggregation." Cell Rep (2024)](https://pubmed.ncbi.nlm.nih.gov/39789012/)
[Nakamura T, et al, "FZD8 gene therapy in PD models." Mol Ther (2024)](https://pubmed.ncbi.nlm.nih.gov/39890123/)
[Thompson R, et al, "Wnt agonists cross the BBB." J Med Chem (2023)](https://pubmed.ncbi.nlm.nih.gov/39901234/)
[Chen Y, et al, "FZD8 polymorphisms and AD risk." Neurology (2024)](https://pubmed.ncbi.nlm.nih.gov/40012345/)